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Expression of GP73, A Resident Golgi Membrane
Protein, in Viral and Nonviral Liver Disease
Raleigh D. Kladney,1 Xiaoyen Cui,2 Gary A. Bulla,2 Elizabeth M. Brunt,3 and Claus J. Fimmel1
GP73 is a novel type II Golgi membrane protein of unknown function that is expressed in the
hepatocytes of patients with adult giant-cell hepatitis (Gene 2000;249:53-65). Its expression
pattern in human liver disease and the regulation of its expression in hepatocytes have not been
systematically studied. The aims of the present study were to compare GP73 protein levels in viral
and nonviral human liver disease and in normal livers, to identify its cellular sources, and to study
the regulation of its expression in hepatoma cells in vitro. GP73 protein levels were quantitated
in explant livers of patients with well-defined disease etiologies and compared with the levels in
normal donor livers. GP73-expressing cells were identified immunohistochemically. GP73 expression in vitro was studied by Western blotting and immunofluorescence microscopy in
HepG2 and SK-Hep-1 cells and in the HepG2-derived, hepatitis B virus (HBV)-transfected
HepG2215 and HepG2T14.1 cell lines. Whole organ levels of GP73 were low in normal livers.
Significant increases were found in liver disease due to viral causes (HBV, HCV) or nonviral
causes (alcohol-induced liver disease, autoimmune hepatitis). In normal livers, GP73 was constitutively expressed by biliary epithelial cells but not by hepatocytes. Hepatocyte expression of
GP73 was dramatically up-regulated in diseased livers, regardless of the etiology, whereas biliary
epithelial cell expression did not change appreciably. GP73 was present at high levels in
HepG2215 cells (a cell line that supports active HBV replication), but was absent in
HepG2T14.1 cells (an HBV-transfected cell line that does not support HBV replication) and in
HBV-free HepG2 cells. In SK-Hep-1 cells, GP73 expression was increased in response to interferon gamma (IFN-␥), and inhibited by tumor necrosis factor ␣ (TNF-␣). In conclusion, increased expression of GP73 in hepatocytes appears to be a general feature of advanced liver
disease, and may be regulated via distinct pathways that involve hepatotropic viruses or cytokines. (HEPATOLOGY 2002;35:1431-1440.)

I

n search of novel, disease-induced hepatocyte proteins we recently identified GP73, a 73-kd resident
Golgi membrane protein of unknown function.
GP73 is a type II transmembrane protein with a single,
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N-terminal transmembrane domain and an extensive, Cterminal coiled-coil domain located on the lumenal surface of the Golgi apparatus.1 A number of structurally
similar Golgi membrane proteins have been identified in
recent years, including p63,2 GPP130/GIMPc,3 and Golgin-84.4 Based on their structural characteristics, several
of these proteins have been implicated in Golgi trafficking. However, their exact biological roles have not been
defined and the regulation of their expression has not
been studied in any detail. Interestingly, the porcine homologue of one of these proteins, p63, was found to be
induced in hepatocytes during circulatory shock, suggesting a potential role in the hepatocyte stress response.5
Our initial studies showed that GP73 was expressed at
high levels in hepatocyte-derived, multinucleated giant
cells in patients with adult giant-cell hepatitis.1 Furthermore, in situ hybridization studies on cirrhotic explant
livers suggested that GP73 messenger RNA levels were
increased in patients with viral hepatitis,6 suggesting a
potential role of the protein in the host response to viral
infection. On the other hand, we found that GP73 was
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normally expressed by epithelial cells in multiple tissues,
including the intestine, trachea, and prostate gland. These
data implied a housekeeping role for GP73 in cells of the
epithelial lineage and provided evidence that multiple
pathways might be involved in the regulation of its expression.
The aims of the present study were 3-fold: (1) to study
the disease-specific expression of GP73 in viral and nonviral liver disease, (2) to identify the hepatic cell types
responsible for GP73 expression in normal and diseased
liver, and (3) to develop suitable in vitro models for the
regulation of GP73 in hepatocyte-derived cell lines.
Our data show that GP73 expression is specifically
up-regulated in hepatocytes in viral and nonviral chronic
liver disease, suggesting that the protein may be involved
in the cellular disease response of hepatocytes. Our in vitro
data point to the existence of separate regulatory pathways
that are activated by infection with hepatotropic viruses or
in response to cytokines.

Materials and Methods
Frozen Liver Tissues. Samples of cryopreserved
(⫺80°C) human explant livers (n ⫽ 70) were obtained
from the Minnesota Tissue Repository (LTPADS, director: Harvey Sharp) and from collaborating investigators.
The samples were obtained from patients with well-characterized end-stage liver disease. Supplemental medical
histories and laboratory data were reviewed to ascertain
the cause of liver disease. Particular attention was paid to
exclude samples in which multiple viral and nonviral
causes of liver disease were present. The following disease
groups were included: chronic hepatitis B virus (HBV)
infection with cirrhosis (n ⫽ 14), chronic hepatitis C
virus (HCV) infection with cirrhosis (n ⫽ 23), alcoholinduced cirrhosis (n ⫽ 9), and cirrhosis caused by autoimmune hepatitis (n ⫽ 7). Control samples were derived
from normal donor livers (n ⫽ 17).
GP73 Protein Measurements. GP73 protein levels
were measured by Western blotting in lysates of human
liver samples and cultured cells. Aliquots of cryopreserved
liver samples (approximately 100 mg per sample) were
homogenized for 1 minute in 20 volumes of lysis buffer
(50 mmol/L Tris-Cl pH 6.8, 5% ␤-mercaptoethanol, 1%
sodium dodecyl sulfate [SDS]), using an SDT Tissumizer
(Tekmar Company, Cincinnati, OH). Lysates were
boiled for 5 minutes, sonicated (3 ⫻ 10-second bursts),
and centrifuged at 14,000 rpm at 4°C for 10 minutes.
The supernatants were stored at ⫺80°C, and subsequently analyzed in batch fashion.
For measurements of GP73 protein in cultured cells,
cells were washed 3 times with phosphate-buffered saline
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(PBS), followed by the addition of 300 L lysis buffer
(62.5 mmol/L Tris-Cl pH 6.8, 20 mmol/L dithiothreitol,
10% glycerol, 1% SDS) per well (6-well plates, surface
area: 962 mm2/well). Adherent cells were dislodged with
plastic scrapers, and the lysates were transferred to microcentrifuge tubes. Samples were boiled for 3 minutes, sonicated for 30 seconds, and centrifuged at 14,000 rpm at
4°C for 20 minutes. The cleared lysates were stored at
⫺80°C, and analyzed in batch fashion.
Protein concentrations in the lysates were determined
using a modification of the micro-Lowry method,7 using
bovine serum albumin as a standard (Sigma Protein Assay
Kit; Sigma, St. Louis, MO). Aliquots corresponding to 15
g of total cellular protein were subjected to SDS-polyacrylamide gel electrophoresis, by using precast 10% TrisHCl gels (Ready Gel; Bio-Rad, Hercules, CA) in a
running buffer containing 25 mmol/L Tris-Cl, 192
mmol/L glycine, and 0.1% SDS. Gels were run at 100 V
for 8 minutes, then 200 V for 30 minutes. A control
sample consisting of 7.5 g of total cellular protein from
293 cells was included in each gel run to allow quantitative comparisons between gels. Separated proteins were
transferred to polyvinylidine difluoride membranes
(PVDF-Plus; Micron Separations, Westborough, MA)
with a semidry transfer cell (Trans-Blot SD; Bio-Rad), by
using an optimized buffer (48 mmol/L Tris-Cl, 39
mmol/L glycine, 0.005% SDS, 20% methanol) and standardized transfer conditions (10 V, 30 minutes). Membranes were kept overnight in blocking buffer (10%
nonfat dry milk in TBST) at 4°C. They were then washed
3 times in wash buffer (0.5% nonfat dry milk in TBST)
and incubated for 1 hour at room temperature in 15 mL
wash buffer containing rabbit polyclonal GP73 antibody
(1:5,000 vol/vol). Several washes with high-salt buffer
(0.5% nonfat dry milk in TBST containing 0.5 mol/L
NaCl) and wash buffer were then performed. This was
followed by an incubation in washing buffer with 1:1,000
vol/vol preadsorbed goat anti-rabbit IgG-HRP conjugate
(Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes. After repeat washes with high-salt and wash buffer,
GP73 immunoreactivity was visualized by enhanced
chemiluminescence and autoradiography, using a commercial kit (ECL; Amersham Pharmacia Biotech, Buckinghamshire, England). Target band intensities were
quantitated by densitometry of the autoradiograms, and
normalized relative to the control signal obtained with
lysates from 293 cells, a cell line that we had previously
found to constitutively express GP73.1
Formalin-Fixed Liver Tissues. Samples of normal
donor livers and from cirrhotic explants were obtained
from the Department of Pathology at Saint Louis University Medical School, from the Pathology Section at the St.
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Louis VA Medical Center, and from collaborating investigators at various institutions throughout the United
States. Samples were fixed overnight in formalin and embedded in paraffin. Sections of approximately 5-m
thickness were then prepared for immunohistochemical
staining.
GP73 Immunohistochemistry. Staining of liver sections was performed by a 2-stage, indirect immunoenzymatic/immunohistochemical technique, using a
commercial kit (DAKO EnVision; Dako Corporation,
Carpinteria, CA). Endogenous peroxidase activity was
blocked by a 5-minute incubation in the presence of
0.03% hydrogen peroxide. Sections were incubated for
30 minutes in the presence of rabbit polyclonal antisera
directed against recombinant GP73 at a dilution of
1:1,000 (vol/vol) as previously described.1 After washes,
the sections were incubated with a peroxidase-labeled
polymer conjugated to goat anti-rabbit immunoglobulin
for 30 minutes. GP73 immunoreactivity was visualized
with the chromogen 3-amino-9-ethylcarbazole (AEC).
Rabbit preimmune sera was used for control experiments.
In some cases, parallel stains were performed to identify
hepatocytes, by using a mouse monoclonal antibody directed against the hepatocyte protein HepPar1 at a dilution of 1:25 (clone OCH1E5; Dako Corporation),8 or to
identify biliary epithelial cells, by using a mouse monoclonal anti-human cytokeratin 19 (CK19) antibody at a
dilution of 1:50 (clone RCK108; Dako Corporation).9 In
these cases, immunoreactivity was visualized using the
chromogen 3,3⬘-diamino-benzidine (DAB). All samples
were counterstained with Mayer’s hematoxylin.
Cell Lines and Culture Conditions. HepG2 and
SK-Hep-1 cells were obtained from the American Tissue
Type Collection (ATCC, Rockville, MD). The cells were
cultured in 6-well plates in the presence of a 1:1 mixture
of Dulbecco’s modified Eagle medium and nutrient mixture F-12 (DMEM-F12) supplemented with 10% fetal
bovine serum (FBS), penicillin, and streptomycin. Tumor necrosis factor ␣ (TNF-␣) was obtained from Life
Technologies (Life Technologies, Gaithersburg, MD).
Recombinant human interferon gamma (IFN-␥) was obtained from Biosource International (Camarillo, CA).
Agonists or the corresponding vehicle solutions in
DMEM-F12 containing 1% FBS were added to subconfluent cells for time periods ranging from 24 to 48 hours.
All experiments involving cultured cells were performed
in triplicate.
HepG2215 and HepG2T14.1 cells were obtained
from Daniela Simon (MCP Hahnemann University,
Philadelphia, PA). HepG2215 cells are HBV-transfected
variants of HepG2 cells that have the ability to replicate
HBV.10 HepG2T14.1 cells were independently derived
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from HepG2 cells by stable transfection with the HBV
genome.11 However, these cells subsequently lost the ability support HBV replication or particle formation in
vitro.12 The cell lines were carried in RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, and 200
g/mL G418.
GP73 Immunofluorescence. Cultured cells were
washed once with PBS prior to fixation, and fixed for 10
minutes in ice-cold methanol containing 4,6-diamidino2-phenylindole (DAPI). After an additional PBS wash,
the slides were incubated for 20 minutes with a blocking
solution containing 4% (vol/vol) goat serum in PBS. This
was followed by a 1-hour incubation with polyclonal rabbit GP73 antibody (1:400 vol/vol in PBS) at room temperature. After 3 PBS washes, slides were washed again
and incubated in PBS containing 4% goat serum and goat
anti-rabbit IgG (1:400 vol/vol) conjugated to Alexa Fluor
488 (Molecular Probes, Eugene, OR). Slides were
mounted in elvanol,13 and viewed using a Nikon Optiphot-2 microscope equipped with epifluorescence. Fluorescent images were photographed using Kodak Elite
CHROME 400 film, and the final images were processed
using Photoshop.
Statistics. GP73 protein levels in the human liver
samples were compared by Kruskal-Wallis one-way analysis of variance (ANOVA).14 Dunn’s method was used to
compare differences between the control and disease
groups.15 A P value of ⬍.05 was considered statistically
significant.
Human Subject Committee Review. All studies were
approved by the Institutional Review Board of the St.
Louis VA Medical Center, the Saint Louis University Human Studies Committee, and the University of Minnesota Human Studies Committee. Patient anonymity was
maintained by labeling of the clinical samples with code
numbers.

Results
GP73 Expression Is Up-regulated in Viral and
Nonviral Liver Disease. GP73 expression was minimal
or nondetectable in most control livers (Fig. 1). GP73
protein levels, as measured by densitometric quantitation
of Western blots, were 0.25 ⫾ 0.14 in normal liver,
17.70 ⫾ 9.20 in HBV, 9.00 ⫾ 4.68 in HCV, 18.10 ⫾
8.15 in alcohol-induced liver disease, and 14.50 ⫾ 4.73 in
autoimmune hepatitis (median ⫾ 25% percentile), corresponding to an increase of up to 70-fold in the disease
groups. Statistical comparisons between the groups of
samples were performed using nonparametric statistical
testing because the data were not normally distributed.
Using Kruskal-Wallis ANOVA on ranks, significant dif-
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Fig. 1. Expression of GP73 in viral and nonviral liver disease. GP73
protein levels were measured by Western blotting in normal donor livers,
and in livers with cirrhosis caused by HBV, HCV, alcohol-induced liver
disease (EtOH), and autoimmune hepatitis (AIH). (A) Western blot of
representative samples. Individual samples from the control and from
each disease group were chosen to closely approximate the median data
shown in B. GP73 protein is detected as a specific band with a molecular
size of approximately 73 kd. (B) Quantitation of GP73 signals in normal
livers (n ⫽ 17), and livers with HBV (n ⫽ 14), HCV (n ⫽ 23), EtOH (n ⫽
9), and AIH (n ⫽ 7). Each data point represents an individual patient
sample. Median values for each group are represented by solid lines
(normal, 0.25; HBV, 17.70; HCV, 9.00; EtOH, 18.10; AIH, 14.50). The
differences between the 4 disease groups and the normal controls was
statistically significant (P ⬍ .05, Kruskal-Wallis ANOVA, Dunn’s Method
[*]). No statistical difference was found between the individual disease
groups.
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ferences were found between the 5 groups of samples (P ⫽
.0000151). Further testing using Dunn’s method revealed that each disease group differed significantly from
the normal controls (P ⬍ .05). On the other hand, no
significant differences were found between the individual
disease groups (P ⬎ .1).
Cellular Sources of GP73 Expression in Normal
Liver. GP73-expressing cells in normal donor livers were
identified by comparing the staining pattern for GP73
with that of known marker proteins for biliary epithelial
cells and hepatocytes (CK19 and HepPar1), respectively
(Fig. 2). GP73 immunoreactivity was consistently detected in biliary epithelial cells in the portal tracts and
throughout the lobules (Fig. 2A). The identity of GP73expressing biliary epithelial cells in portal tracts was confirmed by the costaining with CK19 (2A, 2C). In this cell
type, GP73 immunoreactivity was localized to an area
between the nucleus and apical membrane, typical for a
Golgi distribution in polarized epithelial cells.16 GP73
signals were occasionally detected in hepatocytes located
in zone 1, as shown by the colocalization of GP73 and
HepPar1 (Fig. 2A and D). The majority of hepatocytes,
however, did not express GP73. In hepatocytes, GP73
immunoreactivity was present as discrete lobules, with a
preferential subcellular localization to an area adjacent to
the canalicular membrane. In contrast, the cytoplasm adjacent to the sinusoidal hepatocyte membrane was typically devoid of GP73 signal. This pattern is in agreement
with previous studies on the intracytoplasmic localization
of the Golgi apparatus in normal hepatocytes.16
Cellular Sources of Increased Hepatic GP73 Expression in Advanced Liver Disease. Prominent GP73
signals were detected in hepatocytes in cirrhosis caused by
HBV or HCV infection, alcohol-induced hepatitis, or
autoimmune hepatitis (Fig. 3). In contrast to its sporadic
expression in normal hepatocytes, GP73 was expressed in
virtually every hepatocyte, regardless of the disease etiology. The staining intensity was particularly strong in
hepatocytes that were located adjacent to connective tissue septa and cirrhotic nodules. Similar to the findings in
normal hepatocytes, the subcellular localization of GP73
immunoreactivity appeared to be preferentially pericanalicular. These data suggest that the main change in the
GP73 signal was due to an increase in immunoreactivity
within the same Golgi compartments. However, we cannot rule out subtle changes in GP73 immunolocalization
or in the Golgi morphology in the disease conditions. Bile
duct epithelial reactivity was present as in nondiseased,
normal donor controls. No GP73 immunoreactivity was
found in nonparenchymal liver cells. These data suggest
that the increased GP73 at the whole organ level is due to
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Fig. 2. Cellular sources of GP73 expression in normal liver. GP73 expressing cells in normal liver were identified immunohistochemically, using
GP73-specific rabbit polyclonal antisera. (A) GP73 immunoreactivity was visualized by a two-step method, using the chromogen AEC (red signal).
(B) A control experiment was performed using rabbit preimmune sera. Serial sections were also stained with monoclonal antibodies directed against
(C) CK19, and (D) HepPar1, which were used as markers of biliary epithelial cells and hepatocytes, respectively. DAB was used as a chromogen in
C and D (brown signal). All sections were counterstained with Mayer’s hematoxylin. (A) A prominent GP73 signal was present in biliary epithelial
cells within the portal tracts and throughout the lobules. GP73 immunoreactivity was localized to the perinuclear region of the cells, a pattern that
is characteristic of the Golgi apparatus in polarized epithelial cells. A less prominent signal was detected in occasional hepatocytes in zone 1. (B)
No specific immunoreactivity was obtained with the control sera. (C) CK19 immunoreactivity in biliary epithelial cells. Note the colocalization of the
CK19 signal with the GP73 signal in the same cells shown in A. (D) HepPar1 immunoreactivity in hepatocytes. Note the colocalization of the HepPar1
signal with the GP73 signal in occasional, periportal hepatocytes shown in A. Original magnification ⫻200.

the up-regulation of expression in hepatocytes, and that
this increase is a general feature of advanced liver disease,
regardless of the disease etiology.
GP73 Expression Is Present in HBV-Replicating
Hepatoma Cells. Our in vivo data suggested that viral
infection might represent one mechanism for the increased expression of GP73 in hepatocytes. We addressed
this issue in a cell culture model of HBV infection (Fig. 4).
GP73 expression was measured in highly differentiated HepG2 hepatoma cells, and in HepG2215 and
HepG2T14.1 cells, two cell lines which were independently derived from HepG2 cells by transfection with the
HBV genome. Previous studies by others have shown that
HepG2T14.1 cells—in contrast to HepG2215 cells—do
not support HBV replication and the formation of infectious HBV particles in vitro. Immunofluorescence staining for GP73 in HepG2 cells was negative, reminiscent of

the data obtained in normal hepatocytes in vivo. Similarly, HepG2T14.1 cells did not express GP73. In contrast, a prominent signal was observed in HepG2215
cells. The immunofluorescence data were confirmed by
Western blot analysis, which showed the absence of GP73
expression in HepG2 and HepG2T14.1 cells and a substantial GP73 signal in HepG2215 cells (Fig. 4B). Our
data suggest that active HBV replication may be one of
the pathways that can trigger the expression of GP73 in
hepatocytes.
GP73 Expression In Vitro Is Modulated by Cytokines. The finding of an increased expression of GP73 in
alcohol-induced and autoimmune liver disease suggested
that GP73 expression can be regulated in a virus-independent manner. We tested this possibility by studying GP73
expression in SK-Hep-1 cells, a cell line that spontaneously expresses low levels of GP73. As shown in Fig. 5,
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Fig. 3. Cellular sources of GP73 in advanced liver disease. GP73 expression was studied in representative livers of patients with cirrhosis caused
by (A and B) HBV or HCV infection, (C) alcohol-induced cirrhosis, or (D) cirrhosis caused by autoimmune hepatitis. GP73 immunoreactivity was
visualized using the chromogen AEC (red signal). Background staining: Mayer’s hematoxylin. (A-D) Hepatocytes were strongly reactive for GP73
immunoreactivity, regardless of the cause of the liver disease. Biliary epithelial cells consistently stained positive, with a signal intensity similar to
that observed in normal liver (compare to Fig. 2A). No GP73 staining was detected in inflammatory cells or within the fibrotic septa. Original
magnification ⫻200.

exposure of SK-Hep-1 cells to IFN-␥ resulted in significantly increased levels of GP73, whereas treatment with
TNF-␣ was associated with a reduction in GP73 expression. These data suggest that GP73 expression in hepatocytes may be regulated by cytokines, using pathways that
do not require the presence of viral infection. Together
with the findings in HBV-transfected cells, these results
suggest that the expression of GP73 in hepatocytes may be
controlled by distinct virus-dependent and -independent
mechanisms.

Discussion
GP73 was first identified in a genetic screen for proteins with differential expression in adult giant-cell hepatitis. The screen had originally been designed to isolate
unique complementary DNAs derived from a putative
viral agent thought to be involved in the disease.17 GP73
protein levels were found to be dramatically increased in
the hepatocyte syncytia of patients with giant-cell hepati-

tis. Further experiments showed GP73 to be a novel type
II integral membrane protein that was localized to the
Golgi apparatus.1 In preliminary studies, we found that
GP73 messenger RNA levels were increased in HCVrelated human liver disease.6 These data suggested that
GP73 might function in the hepatocyte response to viral
injury.
The present study was designed to systematically examine the disease- and cell-specific expression patterns of
GP73 in human liver disease. Using explant livers of patients transplanted for HBV, HCV, alcohol- or autoimmune disease–induced cirrhosis, we found striking
increases in GP73 protein expression at the whole organ
level. Similar changes were observed in other forms of
chronic liver disease, including primary biliary cirrhosis,
and primary sclerosing cholangitis.18 Our data clearly establish increased GP73 expression as a general feature of
cirrhotic liver disease, irrespective of the underlying viral
or nonviral disease etiology.
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Fig. 4. GP73 expression in HBVtransfected hepatoma cell lines.
GP73 expression was studied
in monolayers of HBV-transfected
HepG2215 and HepG2T14.1 cells,
and in HepG2 cells. (A) Immunofluorescence studies. Subconfluent
cells were stained using GP73-specific rabbit polyclonal antisera.
GP73 immunoreactivity was visualized by using an Alexa Fluor
488 secondary antibody (green
fluorescence). Cellular DNA was
stained with DAPI (blue fluorescence). No GP73 signal was detected in HepG2 and HepG2T14.1
cells. In contrast, a prominent GP73
signal was present in HepG2215
cells. The GP73 signal was present
in distinct, punctate or tubulovesicular perinuclear structures, typical of
a Golgi distribution in this cell type
(original magnification ⫻100). (B)
GP73 protein levels were quantitated in cellular lysates by Western
blot analysis. Equal amounts of protein (15 g) were loaded in each
lane. GP73 protein was present in
lysate of HepG2215 cells as a specific band of the expected molecular
size. This band was undetectable in
HepG2T14.1 and HepG2 cells.

KLADNEY ET AL.

1437

1438

KLADNEY ET AL.

Fig. 5. Modulation of GP73 expression by cytokines in SK-Hep-1 cells.
SK-Hep-1 cells were grown for 32 hours in the absence (control) or
presence of IFN-␥ (1,000 U/mL) or TNF-␣ (50 ng/mL). Whole cell
lysates were subjected to Western blot analysis, using affinity-purified
rabbit polyclonal antisera directed against recombinant GP73. (A) Data
from a representative experiment. Each lane corresponds to 15 g of
cellular protein. A modest GP73 signal of the anticipated molecular size
(approximately 73 kd) was detected in control cells. IFN-␥ treatment
resulted in an increase of the GP73 signal, whereas incubation in the
presence of TNF-␣ was associated with a substantial decrease in the
GP73 band. The lower molecular weight band (approximately 55 kd) is
nonspecific and represents a cross-reacting protein. (B) Quantitation of
three independent experiments. GP73 levels were expressed as arbitrary
densitometric units, and the control signal was assigned a relative value
of 1. GP73 levels were increased to 2.35 ⫾ 0.07 (mean ⫾ SD) after
IFN-␥ treatment and decreased to 0.10 ⫾ 0.01 after TNF-␣ treatment.
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Our immunohistochemical studies show that the
GP73 signal in normal livers was predominantly derived
from biliary epithelial cells, whereas hepatocytes contributed little to the overall GP73 expression. In contrast,
high-level expression of GP73 was present in diseased
hepatocytes, regardless of the cause of liver disease. GP73
was not expressed in inflammatory cells or in cells within
the cirrhotic septa, and its expression levels in biliary epithelial cells did not appear to be altered. Based on the
decreased percentage of hepatocytes as compared to nonparenchymal cells in cirrhotic liver disease, the degree of
up-regulation of GP73 expression in hepatocytes likely
exceeds the 36- to 72-fold increase measured at the whole
tissue level. This striking increase suggests that GP73 may
function in an important cellular pathway of liver disease.
Our data raise the question as to whether GP73 expression is limited to cirrhotic liver disease, or whether it
occurs during the earlier stages of the disease process. One
way to address this question would be to study liver biopsy
samples of patients with acute hepatitis. However, such
samples are difficult to obtain and typically yield insufficient amounts of material for quantitative protein measurements. An alternative approach would be to study
GP73 expression in explant livers of patients with fulminant hepatic failure without preexisting, chronic liver disease. We have performed preliminary studies on such
tissues and have found increased GP73 expression in surviving hepatocytes (Fimmel, unpublished observations,
March 2002). These data suggest that GP73 up-regulation may be a feature of the early stages of liver disease.
The function of GP73 remains unknown, and multiple search algorithms for protein motifs did not reveal any
obvious catalytic or enzymatic properties. All resident
Golgi proteins are peripheral or integral membrane proteins, and the majority of them are involved in the intracellular modification of secretory proteins. GP73 has no
homologies to the known glycosyltransferases and is unlikely to have catalytic functions in this regard.19 Furthermore, GP73 has no significant sequence homologies or
structural similarities to any of the known nucleotide,
sugar, or ATP transporters of the Golgi apparatus.20 In
recent years, a number of Golgi membrane proteins with
N- or C-terminal membrane anchors similar to GP73
have been described. They include the recently described
Golgin-84,4 p63,2 and GPP130.3 A common feature of
these proteins is the presence of coiled-coil domains in the
N- or C-terminus of the molecule. The biochemical functions of these proteins are unknown, and there are few
studies addressing the regulation of their expression. In
one study, the porcine homologue of p63 was found to be
up-regulated in hepatocytes during cardiogenic shock, a
finding that raises the possibility that the protein might be
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involved in a cellular stress response.5 It has been suggested that their coiled-coil domains function as homotypic or heterotypic protein interaction sites that are
essential for the binding, docking, and trafficking of
transport vesicles to the cisternal membranes. Experiments to test whether GP73 functions in Golgi membrane trafficking are currently ongoing in our laboratory.
In the absence of obvious structural clues for the function of GP73, we utilized in vitro cell culture models to
study its regulation. Our data provide evidence for virusdependent as well as virus-independent modulation of
GP73 expression. In earlier work, we observed that adenovirus infection induced the expression of GP73 in
HepG2 and Hep3B hepatoma cells. GP73 expression in
this model was rapid in onset (within 8 hours of infection), and dependent on the presence of the adenoviral
E1A protein, suggesting regulation at the level of transcription.1 These data prompted us to examine GP73 in a
cell culture model of HBV infection. HepG2215 cells
were originally developed by stable transfection of the
entire HBV genome into HepG2 cells.10 They express the
HBV polyprotein, and support the formation of infectious HBV particles in vitro. As shown in this report,
HepG2215 cells showed robust expression of GP73,
whereas HepG2 cells and HepG2T14.1 cells, an HBVtransfected cell line incapable of supporting productive
HBV infection, did not express GP73.12 These data suggest that GP73 may be expressed in response to infection
with hepatotropic viruses. We hypothesize that GP73
may function in the processing of viral proteins in the
Golgi apparatus or in the formation of infective virions,
and might be beneficial to the invading virus. Alternatively, GP73 might be part of the host cell’s antiviral
response, and might thus be expected to limit viral toxicity or replication. These possibilities can now be elucidated in our in vitro models, for example, by the use of
antisense oligonucleotide technology.
To elucidate potential nonviral mechanisms of GP73
regulation, we hypothesized that GP73 expression might
be modulated by cytokines that play a role in the development or perpetuation of liver disease. We focused our
attention on IFN-␥ and TNF-␣, two pleiotropic cytokines that are involved in many aspects of the initiation
and perpetuation of the hepatic injury response.21,22 Using SK-Hep-1 cells, a cell line that spontaneously expresses moderate levels of GP73, we found that IFN-␥
treatment stimulated GP73 expression approximately
2-fold. The response to IFN-␥ occurred with a lag time of
approximately 14 hours, and peaked at 24 hours, suggesting that the effect occurred as a downstream event in the
intracellular signaling cascade. The IFN-␥ signaling pathway has been extensively studied in recent years. It is

KLADNEY ET AL.

1439

activated by binding of IFN-␥ to a specific receptor,
which is expressed on nearly all cell types, followed by
signaling through JAK1, JAK2, and STAT1. Nuclear
translocation of STAT1 results in the initiation of transcription for a group of approximately 100 genes, which
together play vital roles in the cellular response to viral
infection, and in the regulation of cellular growth and
apoptosis.23 Our data suggest that GP73 represents a
downstream target of IFN-␥ signaling.
In a second set of experiments, we observed that GP73
was down-regulated by TNF-␣. TNF-␣ signaling involves a specific cellular receptor, and a signaling cascade
that requires the activation of the Jun N-terminal kinase.
The pathway involves phosphorylation of the c-Jun
proto-oncogene, which results in the regulation of cellular
genes that play important roles in the regulation of apoptosis, necrosis, and proliferation.21,22,24 Taken together,
these experiments establish that GP73 expression in hepatocytes can be regulated by relevant cytokines, and suggest
that the protein may be an important intracellular target
in the hepatocyte injury response.
Interestingly, IFN-␥ and TNF-␣ had no consistent
effects on GP73 expression in HepG2 and Hep3B cells,
even though both cell lines expressed GP73 in response to
adenovirus infection, and HepG2-derived HepG2215
cells expressed large amounts of the protein. HepG2,
Hep3B, and SK-Hep-1 cells are members of a cluster of
hepatocyte-derived tumor cell lines that are genetically
related but distinct.25 These data suggest that the cytokine
response of GP73 varies in response to the cellular genetic
background.
In addition to its regulated expression via viral and
nonviral pathways, our previous studies suggest that
GP73 is constitutively expressed at high levels in extrahepatic epithelial cells, including intestinal epithelial cells,
pancreatic acinar cells, trachea epithelial cells, and prostate epithelial cells.1 This pattern is reminiscent of the
consistent GP73 expression in normal biliary epithelial
cells and suggests GP73 has housekeeping functions in
cells of the epithelial lineage.
To date, few studies have been performed on the role
of the Golgi apparatus and its associated proteins in
disease states.26 Our study provides a suitable model to
address the involvement of this organelle in human
liver disease. Further experiments are needed to elucidate the function of GP73, using protein overexpression, antisense oligonucleotide inhibition, and the
identification of potential interacting protein in normal and diseased cells.
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